McGuire W L, Clark G M
CA Cancer J Clin. 1986 Sep-Oct;36(5):302-9. doi: 10.3322/canjclin.36.5.302.
It has been demonstrated that progesterone receptors (PRs) are at least as valuable as estrogen receptors (ERs) for predicting outcome in breast cancer patients. Retrospective analysis indicates that the presence of PRs may be the second most critical factor, after the number of positive nodes, in predicting disease-free survival, with a correlation between length of survival and number of tumor PRs. The presence of PRs has been shown to be of value for predicting response in both early and advanced breast cancer patients. In studies of assay consistency, major discordance rates were minimal in simultaneous assays, but extremely high in sequential assays of tumors that were PR-positive in initial assay. The responsible factor was interim endocrine therapy, and it was subsequently determined that the prognosis was worse for those patients whose tumors lost PR between assays.
已经证明，孕酮受体（PRs）在预测乳腺癌患者的预后方面至少与雌激素受体（ERs）一样有价值。回顾性分析表明，PRs的存在可能是预测无病生存期的第二关键因素，仅次于阳性淋巴结数量，生存期长度与肿瘤PRs数量之间存在相关性。PRs的存在已被证明对预测早期和晚期乳腺癌患者的反应均有价值。在检测一致性研究中，同时检测时主要不一致率最低，但在初始检测中PR阳性的肿瘤的序贯检测中极高。相关因素是中期内分泌治疗，随后确定，那些肿瘤在检测之间失去PR的患者预后更差。
